The fusion inhibitor enfuvirtide in recent antiretroviral strategies

Current Opinion in HIV and AIDS

Volumn 4, Issue 2, 2009, Pages 150-158

  Makinson, Alain ^a   Reynes, Jacques ^a,b,c  

^a MONTPELLIER UNIVERSITY HOSPITAL   (France)

^b UNIV MONTPELLIER   (France)

^c GUI DE CHAULIAC HOSPITAL   (France)

Author keywords

Antiretroviral therapy; Enfuvirtide; Fusion inhibitor; HIV

Indexed keywords

DARUNAVIR; DARUNAVIR PLUS RITONAVIR; ENFUVIRTIDE; ETRAVIRINE; LOPINAVIR; MARAVIROC; RALTEGRAVIR; RITONAVIR PLUS TIPRANAVIR; TIPRANAVIR; VICRIVIROC; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; GLYCOPROTEIN GP 41; PEPTIDE FRAGMENT;

CEREBROSPINAL FLUID; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; ECCHYMOSIS; ERYTHEMA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INJECTION SITE PAIN; INJECTION SITE REACTION; KIDNEY FAILURE; PATIENT COMPLIANCE; PEDIATRICS; PREGNANT WOMAN; PRIORITY JOURNAL; PROPHYLAXIS; QUALITY OF LIFE; REVIEW; SKIN INDURATION; TREATMENT FAILURE; UMBILICAL CORD; VIROLOGY; VIRUS LOAD; VIRUS RESISTANCE; VIRUS TRANSMISSION; CHEMOPROPHYLAXIS; DISEASE TRANSMISSION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; METHODOLOGY; TREATMENT OUTCOME;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CHEMOPREVENTION; CLINICAL TRIALS AS TOPIC; HIV ENVELOPE PROTEIN GP41; HIV INFECTIONS; HUMANS; INFECTIOUS DISEASE TRANSMISSION, VERTICAL; PEPTIDE FRAGMENTS; TREATMENT OUTCOME;

EID: 65549115032     PISSN: 1746630X     EISSN: 17466318     Source Type: Journal    
DOI: 10.1097/COH.0b013e32832498d8     Document Type: Review

References (46)

1. Lazzarin A, Clotet B, Cooper D, et al. Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia. N Engl J Med 2003; 348:2186-2195. (Pubitemid 36618129)
2. Lalezari JP, Henry K, O'Hearn M, et al. Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. N Engl J Med 2003; 348:2175-2185. (Pubitemid 36618128)
3. Raffi F, Katlama C, Saag M, et al. Week-12 response to therapy as a predictor of week 24, 48, and 96 outcome in patients receiving the HIV fusion inhibitor enfuvirtide in the T-20 versus Optimized Regimen Only (TORO) trials. Clin Infect Dis 2006; 42:870-877. (Pubitemid 43363947)
4. Peuchant O, Capdepont S, Ragnaud JM, et al. Primary resistance to enfuvirtide (T20) in recently HIV-1 infected, antiretroviral-naive patients from the ANRS Aquitaine Cohort. Antivir Ther 2007; 12:559-562.
5. Si-Mohamed A, Piketty C, Tisserand P, et al. Increased polymorphism in the HR-1 gp41 env gene encoding the enfuvirtide (T-20) target in HIV-1 variants harboring multiple antiretroviral drug resistance mutations in the pol gene. J Acquir Immune Defic Syndr 2007; 44:1-5. (Pubitemid 46052213)
6. Tebas P, Bellos N, Lucasti C, et al. Enfuvirtide does not require dose adjustment in patients with chronic kidney failure: results of a pharmacokinetic study of enfuvirtide in HIV-1-infected patients with impaired kidney function. J Acquir Immune Defic Syndr 2008; 47:342-345. (Pubitemid 351619421)
7. Price RW, Parham R, Kroll JL, et al. Enfuvirtide cerebrospinal fluid (CSF) pharmacokinetics and potential use in defining CSF HIV-1 origin. Antivir Ther 2008; 13:369-374. (Pubitemid 352016729)
8. de Requena DG, Bonora S, Castagna A, et al. Pharmacokinetic and pharmacodynamic determinants of early virological response to enfuvirtide-based regimens in HIV-positive patients. J Antimicrob Chemother 2008; 62:384-387. (Pubitemid 351984786)
9. Raffi F, Battegay M, Rusconi S, et al. Combined tipranavir and enfuvirtide use associated with higher plasma tipranavir concentrations but not with increased hepatotoxicity: sub-analysis from RESIST. AIDS 2007; 21:1977-1980. (Pubitemid 47333873)
10. Kakuda T, Scholler-Gyure M, Peeters M, et al. Pharmacokinetics of etravirine (ETR; TMC125) are not affected by sex, age, race, use of enfuvirtide (ENF) or treatment duration in HIV-1-infected subjects; tenofovir and HCV affect levels. In: 9th International Workshop on Clinical Pharmacology of HIV Therapy 2008; New Orleans; 7-9 April 2008.
11. Reynes J, Arasteh K, Clotet B, et al. TORO: ninety-six-week virologic and immunologic response and safety evaluation of enfuvirtide with an optimized background of antiretrovirals. AIDS Patient Care STDS 2007; 21:533-543. A follow-up of TORO trials that shows long-term 96-week virological responses in patients with undetectable HIV viral load at week 48. (Pubitemid 350194955)
12. Haubrich R, Berger D, Chiliade P, et al. Week 24 efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients. AIDS 2007; 21:F11-F18. A randomized phase II trial that shows enhanced virological efficacy of combinations, including darunavir/ritonavir and enfuvirtide. (Pubitemid 46568621)
13. Katlama C, Esposito R, Gatell JM, et al. Efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients: 24-week results of POWER 1. AIDS 2007; 21:395-402. A randomized phase II trial that shows enhanced virological efficacy of combinations, including darunavir/ritonavir and enfuvirtide. (Pubitemid 46263249)
14. Clotet B, Bellos N, Molina JM, et al. Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials. Lancet 2007; 369:1169-1178. (Pubitemid 46541620)
15. Dejesus E, Gottlieb MS, Gathe JC Jr, et al. Safety and efficacy of enfuvirtide in combination with darunavir/ritonavir and an optimized background regimen in triple-class experienced HIV-infected patients: the BLQ study. Antimicrob Agents Chemother 2008; 52:4315-4319. A single-arm trial that evaluates efficacy of darunavir/ritonavir and enfuvirtide in salvage combinations for HIV-multidrug-experienced patients.
16. Madruga JV, Cahn P, Grinsztejn B, et al. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial. Lancet 2007; 370:29-38. A randomized phase III trial that shows high proportions of complete responders with etravirine and darunavir/ritonavir, not enhanced by enfuvirtide when Phenotypic Sensibility Scores at least 2. (Pubitemid 47017466)
17. Lazzarin A, Campbell T, Clotet B, et al. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial. Lancet 2007; 370:39-48. A randomized phase III trial that shows high proportions of complete responders with etravirine and darunavir/ritonavir, not enhanced by enfuvirtide when Phenotypic Sensibility Scores at least 2. (Pubitemid 47017467)
18. Steigbigel RT, Cooper DA, Kumar PN, et al. Raltegravir with optimized background therapy for resistant HIV-1 infection. N Engl J Med 2008; 359:339-354.
19. Cooper DA, Steigbigel RT, Gatell JM, et al. Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection. N Engl J Med 2008; 359:355-365. Results of the subgroup analysis of the two BENCHMRK studies, which show enhanced virological responses with enfuvirtide (or darunavir).
20. Zingman B, Suleiman J, DeJesus E, et al. Vicriviroc in combination therapy with an optimized antiretroviral regimen for treatment-experienced subjects: the VICTOR-E1 trial [abstract #795]. In: 15th Conference on Retroviruses and Opportunistic Infections 2008; Boston, Massachusetts; 3-6 February 2008. A phase II vicriviroc study that shows increased virological responses with enfuvirtide, even when two other fully active drugs, including vicriviroc, are present.
21. Gulick RM, Lalezari J, Goodrich J, et al. Maraviroc for previously treated patients with R5 HIV-1 infection. N Engl J Med 2008; 359:1429-1441.
22. Fatkenheuer G, Nelson M, Lazzarin A, et al. Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection. N Engl J Med 2008; 359:1442-1455. A phase III trial of maraviroc that demonstrates that first-time use of enfuvirtide in patients with no history of enfuvirtide use, compared with placebo arm, is statistically associated with a favourable virological outcome.
23. Wiznia A, Church J, Emmanuel P, et al. Safety and efficacy of enfuvirtide for 48 weeks as part of an optimized antiretroviral regimen in pediatric human immunodeficiency virus 1-infected patients. Pediatr Infect Dis J 2007; 26:799-805. This paper describes a single-arm trial and first experience in paediatric population. (Pubitemid 47329850)
24. Haberl A, Linde R, Reitter A, et al. Use of enfuvirtide in HIV+ pregnant women [abstract #627b]. In: 15th Conference on Retroviruses and Opportunistic Infections 2008; Boston, Massachusetts; 3-6 February 2008.
25. Ceccaldi PF, Ferreira C, Gavard L, et al. Placental transfer of enfuvirtide in the ex vivo human placenta perfusion model. Am J Obstet Gynecol 2008; 198:433 e1-433 e2.
26. Gasnault J, Chavez H, Dorofeev E, et al. Acceleration of immune recovery on intensified ART improves survival in patients with AIDS-related progressive multifocal leukoencephalopathy: preliminary reports of the ANRS 125 trial [abstract #379]. In: 14th Conference on Retroviruses and Opportunistic Infections 2007; Los Angeles, California; 25-28 February 2007.
27. Gasnault J, Lanoy E, Bentata M, et al. Intracerebral penetrating ART are more efficient on survival of HIV+ patients with progressive multifocal leucoencephalopathy (ANRS CO4 - FHDH) [abstract #385]. In: 15th Conference on Retroviruses and Opportunistic Infections 2008; Boston, Massachusetts; 3-6 February 2008.
28. Reynes J, Pellegrin I, Peytavin G, et al. INDEED study: final results of an induction treatment strategy with enfuvirtide in treatment failure patients [abstract #P029]. In: Ninth International Congress on Drug Therapy in HIV Infection 2008; Glasgow, UK; 9-13 November 2008.
29. Clotet B, Capetti A, Soto-Ramirez LE, et al. A randomized, controlled study evaluating an induction treatment strategy in which enfuvirtide was added to an oral, highly active antiretroviral therapy regimen in treatment- experienced patients: the INTENSE study. J Antimicrob Chemother 2008; 62:1374-1378.
30. Markowitz M, Nguyen BY, Gotuzzo E, et al. Rapid and durable antiretroviral effect of the HIV-1 integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: results of a 48-week controlled study. J Acquir Immune Defic Syndr 2007; 46:125-133. (Pubitemid 47482607)
31. Saag M, Ive P, Heera J, et al. A multicenter, randomized, double-blind, comparative trial of a novel CCR5 antagonist, maraviroc versus efavirenz, both in combination with combivir (zidovudine [ZDV]/lamivudine [3TC]), for the treatment of antiretroviral naive patients infected with R5 HIV 1: week 48 results of the MERIT study. In: 4th IAS Conference on HIV Pathogenesis, Treatment and Prevention 2007; Sydney, Australia; 22-25 July 2007.
32. Harris M, Larsen G, Montaner JS. Outcomes of multidrug-resistant patients switched from enfuvirtide to raltegravir within a virologically suppressive regimen. AIDS 2008; 22:1224-1226.
33. Towner W, Klein D, Follansbee S, et al. Pilot study of switching enfuvirtide to raltegravir in HIV-1 positive patients well controlled on an enfuvirtide based regimen. In: XVII International AIDS Conference; Mexico; 3-8 August 2008. A pilot study, prospective, of raltegravir switch to enfuvirtide without modification of background ART.
34. Deeks SG, Lu J, Hoh R, et al. Interruption of enfuvirtide in HIV-1 infected adults with incomplete viral suppression on an enfuvirtide-based regimen. J Infect Dis 2007; 195:387-391. (Pubitemid 46146116)
35. Carsenti-Dellamonica H, Durant M, Ticchioni M, et al. Enfuvirtide therapy increases naïve and central memory CD4 T cells, decreases the level of immune activation and apoptosis [abstract #446]. In: 15th Conference on Retroviruses and Opportunistic Infections 2008; Boston, Massachusetts; 3-6 February 2008.
36. Barretina J, Blanco J, Bonjoch A, et al. Immunological and virological study of enfuvirtide-treated HIV-positive patients. AIDS 2004; 18:1673-1682. (Pubitemid 39095784)
37. Shepard BD, Loutfy MR, Raboud J, et al. Early changes in T-cell activation predict antiretroviral success in salvage therapy of HIV infection. J Acquir Immune Defic Syndr 2008; 48:149-155.
38. Carcelain G, Blanc C, Leibowitch J, et al. T cell changes after combined nucleoside analogue therapy in HIV primary infection. AIDS 1999; 13:1077-1081. (Pubitemid 29361398)
39. Garg H, Joshi A, Freed EO, Blumenthal R. Site-specific mutations in HIV-1 gp41 reveal a correlation between HIV-1-mediated bystander apoptosis and fusion/hemifusion. J Biol Chem 2007; 282:16899-16906. (Pubitemid 47093247)
40. Yang X, Kurteva S, Ren X, et al. Stoichiometry of envelope glycoprotein trimers in the entry of human immunodeficiency virus type 1. J Virol 2005; 79:12132-12147. (Pubitemid 41348726)
41. Melby TE, Despirito M, Demasi RA, et al. Association between specific enfuvirtide resistance mutations and CD4 cell response during enfuvirtide-based therapy. AIDS 2007; 21:2537-2539.
42. Svicher V, Aquaro S, D'Arrigo R, et al. Specific enfuvirtide-associated mutational pathways in HIV-1Gp41 are significantly correlated with an increase in CD4(+) cell count, despite virological failure. J Infect Dis 2008; 197:1408-1418. (Pubitemid 351706465)
43. Descamps D, Assoumou L, Masquelier B, et al. HIV-1-infected patients from the French National Observatory experiencing virological failure while receiving enfuvirtide. J Antimicrob Chemother 2008; 62:451-455.
44. Ray N, Harrison JE, Blackburn LA, et al. Clinical resistance to enfuvirtide does not affect susceptibility of human immunodeficiency virus type 1 to other classes of entry inhibitors. J Virol 2007; 81:3240-3250. (Pubitemid 46456633)
45. Wright D, Rodriguez A, Godofsky E, et al. Efficacy and safety of 48 weeks of enfuvirtide 180 mg once-daily dosing versus 90 mg twice-daily dosing in HIV-infected patients. HIV Clin Trials 2008; 9:73-82. (Pubitemid 351804393)
46. Boyd MA, Truman M, Hales G, et al. A randomized study to evaluate injection site reactions using three different enfuvirtide delivery mechanisms (the OPTIONS study). Antivir Ther 2008; 13:449-453. A quality-of-life and site-reaction study that evaluates three different enfuvirtide delivery mechanisms. (Pubitemid 352022554)